Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scans reveal Ibogaine's effects on opioid cravings

NCT ID NCT07226570

Knowledge-focused Sponsor: University of California, Irvine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study uses brain scans (MRI, MRS, EEG) to see how ibogaine affects the brain in 20 people with moderate to severe opioid use disorder. Participants will already be receiving legal ibogaine treatment outside the U.S. The research team only observes and measures brain activity, cravings, and withdrawal symptoms before and after treatment. The goal is to understand how ibogaine might work in the brain, not to test if it is a safe or effective treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ibogaine
What this could lead to
If successful, this study could help explain how ibogaine affects the brain in opioid use disorder, potentially guiding future treatments.
What could go wrong
This is a very small observational study (20 people) where researchers do not provide the treatment. It cannot prove ibogaine works or is safe, only explore brain changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults ages 21 to 70 with a confirmed diagnosis of moderate to severe opioid use disorder (OUD), defined as meeting four or more symptoms according to DSM-5 criteria. Participants must be independently scheduled to receive ibogaine treatment at a licensed clinic outside the United States.

Ages

21 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 21-70 with confirmed moderate to severe OUD as assessed by equal or greater than 4 symptoms using DSM-5 criteria. * Independently scheduled to receive ibogaine treatment at Ambio Life Sciences in Tijuana, Mexico. * Able to undergo MRI and EEG procedures at UC Irvine at Visit 1 (baseline), Visit 4, and Visit 5, totaling three sessions. * Able to complete psychometric surveys at each study time point. * Able to provide urine samples at all three scanning sessions at UCI. * Able to provide urine samples at a local external lab for 3- and 6-month follow-ups. * Capable of giving written informed consent. * Proficient ability to speak, read, and write in English. Exclusion Criteria: * Presence of known past procedures, devices in the body, claustrophobia, or other contraindications for MRI. * Use of any psychedelic substances within 3 months prior to screening. * Diagnosis of schizophrenia, bipolar disorder (type I or II), or borderline personality disorder. * Use of ibogaine within 6 months prior to screening. * Pregnant or nursing. Participants who become pregnant during the study will be withdrawn from further participation. * Diagnosis of epilepsy or history of seizures. * Other contraindications to MRI/EEG methods. These may include but are not limited to: brain surgical clips and surgical staples, metal implants in the brain, and certain metallic dental material. * Inability to complete MRI/EEG sessions or follow-up visits. * Inability or unwillingness of an individual to give written informed consent. Note: UCI does not sponsor or financially support the ibogaine treatment in any way; all treatment costs are the sole responsibility of the participant.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Opioid use disorder (OUD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Opioid use disorder (OUD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Susan Samueli Integrative Health Institute, University of California, Irvine

    RECRUITING

    Irvine, California, 92617, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.